Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

RXII

RXI Pharmaceuticals Corporation (RXII)

Rxi Pharmaceuticals Corp. (MM)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RXII
FechaHoraFuenteTítuloSímboloCompañía
15/02/201906:15PR Newswire (US)Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/12/201808:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
19/11/201816:52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201806:10PR Newswire (US)RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201806:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
07/11/201806:05PR Newswire (US)RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell T...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
06/11/201806:05PR Newswire (US)RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/10/201813:00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
03/10/201815:31PR Newswire (US)RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public OfferingNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/10/201816:32Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/10/201816:30Edgar (US Regulatory)Post-effective Amendment Filed Solely to Add Exhibits to a Registration Statement (pos Ex)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201805:39Edgar (US Regulatory)Registration of Additional Securities (up to 20%) (s-1mef)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201805:36Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201805:10PR Newswire (US)RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public OfferingNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/09/201805:14Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
26/09/201807:00PR Newswire (US)RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intra...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/09/201816:48Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
31/08/201816:32Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/08/201808:15PR Newswire (US)RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
24/08/201816:04Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
17/08/201816:02Edgar (US Regulatory)Amended Small Company Offering and Sale of Securities Without Registration (d/a)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
15/08/201808:25PR Newswire (US)RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/08/201808:15PR Newswire (US)RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate HighlightsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
07/08/201806:15PR Newswire (US)RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/08/201808:25PR Newswire (US)RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and JapanNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/08/201808:25PR Newswire (US)RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal ScarringNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/06/201807:00PR Newswire (US)BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the T...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
18/05/201810:58PR Newswire (US)RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common WartsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
11/05/201806:05PR Newswire (US)RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Te...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/05/201806:05PR Newswire (US)RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate HighlightsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
 Showing the most relevant articles for your search:NASDAQ:RXII